secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2025-08-19T23:59:59+00:00
Accession:  0001193125-25-183073
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rein Therapeutics gets UK MHRA nod for Phase 2 IPF trial of LTI-03
------------------------------------------------------------------

- UK MHRA authorized Phase 2 'RENEW' trial of LTI-03 for idiopathic pulmonary fibrosis (IPF).
- Trial will enroll up to 120 patients globally; two dose groups vs placebo over 24 weeks.
- Primary endpoint: safety/tolerability; secondary: lung function and imaging-based fibrosis measures.
- Patient recruitment in UK to begin soon; initial data expected in 2026.
- LTI-03 is first-in-class, designed to target fibrosis and protect lung regeneration; IPF median survival is 3-5 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525183073/0001193125-25-183073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525183073/d938122d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-183073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer